Table 3.
Comparison of clinical outcomes of fixed‐dose vs free combination of RAS inhibitor and thiazide diuretic
| Outcomes | Group | Event number | Person‐year | Incidence rate (per 100 person‐year) | Hazard ratio (95% confidence interval) | P‐value |
|---|---|---|---|---|---|---|
| Primary end point (MACE) | Free combination | 293 | 10 941.830 | 2.678 | 1 | (Reference) |
| Fixed‐dose | 785 | 34 495.321 | 2.276 | 0.85 (0.74‐0.97) | 0.017 | |
| Hospitalization for heart failure | Free combination | 108 | 11 258.419 | 0.959 | 1 | (Reference) |
| Fixed‐dose | 257 | 35 402.573 | 0.726 | 0.76 (0.6‐0.95) | 0.015 | |
| New diagnosis of CKD | Free combination | 407 | 10 751.701 | 3.785 | 1 | (Reference) |
| Fixed‐dose | 1164 | 33 971.951 | 3.426 | 0.91 (0.81‐1.01) | 0.087 | |
| New initiation of dialysis | Free combination | 80 | 11 343.786 | 0.705 | 1 | (Reference) |
| Fixed‐dose | 173 | 35 600.836 | 0.486 | 0.69 (0.53‐0.89) | 0.005 |
CKD, chronic kidney disease; MACE, major adverse cardiac events; RAS, renin‐angiotensin system.